Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTONEL WITH CALCIUM (COPACKAGED) vs ACTONEL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ACTONEL WITH CALCIUM (COPACKAGED) contains risedronate sodium, a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inhibiting farnesyl pyrophosphate synthase (FPPS), an enzyme in the mevalonate pathway. This leads to reduced bone turnover and increased bone mineral density. The calcium component is for supplementation to prevent hypocalcemia.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and interfering with osteoclast activity.
Treatment and prevention of postmenopausal osteoporosis,Treatment of glucocorticoid-induced osteoporosis,Treatment of Paget's disease of bone
Treatment of Paget's disease of bone,Treatment of osteoporosis in postmenopausal women,Prevention of osteoporosis in postmenopausal women,Treatment of glucocorticoid-induced osteoporosis,Off-label: Prevention of bone metastases in some cancers
Actonel (risedronate) 35 mg orally once weekly, taken with 6-8 oz of plain water at least 30 minutes before breakfast. Calcium supplement (e.g., 1250 mg calcium carbonate) taken with food at a different time of day.
35 mg orally once weekly or 5 mg orally once daily for osteoporosis; also 30 mg orally once weekly for Paget disease.
Terminal elimination half-life of risedronate is approximately 20 hours for the 5 mg daily dose and 480 hours for the 35 mg weekly dose due to prolonged retention in bone; clinically, the drug accumulates in bone and is slowly released.
Terminal elimination half-life: 1.5-2 hours (short for bisphosphonates due to rapid renal clearance); however, bone retention half-life is prolonged (>1 year) due to binding to hydroxyapatite.
Risedronate is not metabolized and is eliminated unchanged primarily via renal excretion.
Not metabolized; excreted unchanged in urine.
Risedronate is eliminated primarily via renal excretion, with approximately 50% of an absorbed dose excreted unchanged in urine. Unabsorbed drug is eliminated in feces. Total clearance is about 100 m L/min.
Renal: 50-60% unchanged via glomerular filtration and active tubular secretion; Fecal: minor, biliary excretion negligible.
Risedronate is approximately 24% bound to plasma proteins.
~24% bound to plasma proteins (primarily albumin).
Volume of distribution for risedronate is approximately 6.3 L/kg, indicating extensive distribution into bone and other tissues.
Vd: 0.5-1 L/kg, indicating distribution primarily into bone and extracellular fluid.
Oral bioavailability of risedronate is low, averaging 0.63% for the 5 mg tablet when taken under fasting conditions; administration with food reduces bioavailability significantly (by up to 50%).
Oral: 0.5-1% under fasting conditions (low due to poor intestinal absorption and high first-pass effect); reduced by 60-90% with food or calcium-containing beverages.
Contraindicated if Cr Cl <30 m L/min. For Cr Cl 30-49 m L/min: no dose adjustment needed. For Cr Cl ≥50 m L/min: no adjustment.
Contraindicated if Cr Cl <30 m L/min. If Cr Cl 30-49 m L/min, no adjustment needed. If Cr Cl <30 m L/min, do not use.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe impairment (Child-Pugh C).
No dose adjustment required for mild to moderate hepatic impairment. Not studied in severe hepatic impairment (Child-Pugh C); use caution.
Not indicated for use in pediatric patients. Safety and efficacy not established.
Safety and efficacy not established in pediatric patients. Not recommended for use in children.
No specific dose adjustment required. Caution in patients with decreased renal function; monitor renal status. Increased risk of hypocalcemia if calcium intake inadequate.
No dose adjustment based on age alone. Monitor renal function. Ensure adequate calcium and vitamin D intake. Same dosing as adults.
None
None.
Hypocalcemia must be corrected before therapy,Severe renal impairment (Cr Cl <30 m L/min) is not recommended,Esophageal irritation: instruct patients to swallow with full glass of water and not to lie down for 30 minutes,Osteonecrosis of the jaw (rare, mainly with cancer doses),Atypical femur fractures (rare, with long-term use),Avoid concomitant use with other bisphosphonates
Hypocalcemia must be corrected before therapy,Esophageal irritation and potential for esophageal cancer,Renal impairment (creatinine clearance <30 m L/min) requires dose adjustment or avoidance,Osteonecrosis of the jaw (usually with cancer treatments),Atypical femur fractures with long-term use,Musculoskeletal pain
Hypocalcemia,Severe renal impairment (Cr Cl <30 m L/min),Inability to sit or stand upright for at least 30 minutes,Hypersensitivity to risedronate or any component,Use in patients with esophageal abnormalities that delay emptying (e.g., stricture, achalasia)
Hypocalcemia,Inability to stand or sit upright for at least 30 minutes,Severe renal impairment (Cr Cl <30 m L/min),Hypersensitivity to risedronate or any component
Risedronate absorption is significantly reduced by food, especially dairy products, calcium-rich foods, and beverages other than plain water. Avoid all food, beverages (except plain water), and other medications for at least 30 minutes after the dose. Calcium supplement should be taken with a meal to enhance absorption.
Calcium, magnesium, iron, and aluminum (e.g., antacids) bind risedronate and reduce absorption. Separate by at least 30 minutes after taking risedronate. Avoid mineral water, dairy products, and calcium-fortified juices within 30 minutes of dosing.
Risedronate: Pregnancy Category C. Bisphosphonates accumulate in bone and are released slowly; theoretical risk of fetal skeletal abnormalities if exposure occurs before or during pregnancy. No adequate studies in pregnant women; use only if clearly needed. Calcium carbonate: Generally considered safe but excessive doses may cause hypercalcemia-related fetal risks. First trimester: Limited data, avoid if possible. Second/third trimester: Use only if maternal benefit outweighs fetal risk.
Pregnancy Category C. No adequate studies in pregnant women. In animal studies, bisphosphonates cause fetal skeletal abnormalities at high doses. Risk cannot be ruled out; use only if clearly needed. First trimester: potential for skeletal effects; second and third trimesters: risk of fetal hypocalcemia and skeletal retardation. Discontinue if pregnancy occurs.
Risedronate: Unknown if excreted in human milk; not recommended due to potential for bone growth inhibition. Calcium: Excreted in breast milk at normal maternal intake levels; no adverse effects reported. M/P ratio: Unknown for risedronate; calcium M/P ratio approximately 1.1.
Unknown if excreted in human milk. M/P ratio not established. Caution advised; consider alternative treatments during breastfeeding.
Risedronate: No specific dose adjustments are recommended in pregnancy due to lack of data; generally avoided. Calcium: No dose adjustment needed; maintain recommended daily intake (1000-1300 mg/day). Pregnancy may increase calcium absorption but no dose change required for supplementation.
No specific pharmacokinetic data during pregnancy. Dose adjustments not routinely recommended; consider discontinuation due to potential fetal risks.
Actonel (risedronate) with calcium (copackaged) is used for osteoporosis. Administer risedronate on an empty stomach with plain water, at least 30 minutes before first food, drink, or other medications. Wait at least 30 minutes after risedronate before taking the calcium supplement. Calcium can interfere with risedronate absorption.
Actonel (risedronate) is a bisphosphonate for osteoporosis and Paget's disease. Administer on an empty stomach with plain water (not mineral water) at least 30 minutes before the first food, beverage, or other medication. Avoid in Cr Cl <30 m L/min. Monitor for hypocalcemia before treatment. Counsel on atypical femur fractures and osteonecrosis of the jaw (ONJ), especially with dental procedures.
Take the risedronate tablet first thing in the morning, at least 30 minutes before eating or drinking anything except plain water.,Swallow the risedronate tablet whole with a full glass of plain water (6-8 oz). Do not crush, chew, or suck the tablet.,Do not lie down for at least 30 minutes after taking risedronate to reduce risk of esophageal irritation.,After taking risedronate, wait at least 30 minutes before taking the calcium supplement provided in the copack.,Take the calcium supplement with food or after a meal to improve absorption and reduce stomach upset.,Report any symptoms of esophageal problems (difficulty or pain on swallowing, heartburn, or retrosternal pain) or jaw pain (possible osteonecrosis of the jaw).
Take Actonel first thing in the morning with a full glass of plain water (6-8 oz) at least 30 minutes before any food, drink, or other medicine.,Do not lie down for at least 30 minutes after taking to reduce risk of esophageal irritation.,Avoid mineral water, coffee, tea, juice, or calcium-rich beverages as they can reduce absorption.,Report severe bone, joint, or muscle pain; jaw pain or numbness; or signs of hypocalcemia (muscle cramps, tingling).,Maintain adequate calcium and vitamin D intake as directed by your doctor.,If you miss a dose, skip it and resume next morning; do not take two doses on the same day.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTONEL WITH CALCIUM (COPACKAGED) vs ACTONEL, answered by our medical review team.
ACTONEL WITH CALCIUM (COPACKAGED) is a Bisphosphonate and Calcium Supplement that works by ACTONEL WITH CALCIUM (COPACKAGED) contains risedronate sodium, a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inhibiting farnesyl pyrophosphate synthase (FPPS), an enzyme in the mevalonate pathway. This leads to reduced bone turnover and increased bone mineral density. The calcium component is for supplementation to prevent hypocalcemia.. ACTONEL is a Bisphosphonate that works by Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and interfering with osteoclast activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTONEL WITH CALCIUM (COPACKAGED) and ACTONEL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTONEL WITH CALCIUM (COPACKAGED) is: Actonel (risedronate) 35 mg orally once weekly, taken with 6-8 oz of plain water at least 30 minutes before breakfast. Calcium supplement (e.g., 1250 mg calcium carbonate) taken with food at a different time of day.. The standard adult dose of ACTONEL is: 35 mg orally once weekly or 5 mg orally once daily for osteoporosis; also 30 mg orally once weekly for Paget disease.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTONEL WITH CALCIUM (COPACKAGED) and ACTONEL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTONEL WITH CALCIUM (COPACKAGED) is classified as Category C. Risedronate: Pregnancy Category C. Bisphosphonates accumulate in bone and are released slowly; theoretical risk of fetal skeletal abnormalities if exposure occurs before or during . ACTONEL is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. In animal studies, bisphosphonates cause fetal skeletal abnormalities at high doses. Risk cannot be ruled out; use only. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.